v3.19.3.a.u2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities:      
Net loss $ (314,925) $ (153,040) $ (305,250)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:      
Depreciation and amortization 93,807 97,344 102,093
Non-cash interest 8,731 4,903 2,575
Amortization of deferred financing costs 995 187 224
Losses from investments in investees 2,900 14,497 14,471
Equity-based compensation – employees and non-employees 13,421 21,761 28,307
Asset impairment charges 92,399 21,778 13,194
Realized loss (gain) on disposal of fixed assets and sales of equity securities and other 739 46 (8,663)
Change in fair value of equity securities and derivative instruments and other 8,748 (6,524) (52)
Change in fair value of contingent consideration (14,854) (16,816) (3,423)
Deferred income tax provision (benefit) 4,324 (35,133) 16,092
Changes in assets and liabilities, net of the effects of acquisitions:      
Accounts receivable, net 7,376 20,397 58,011
Inventory, net (12,133) 4,590 (3,539)
Other current assets and prepaid expenses (11,486) 2,276 4,771
Other assets 409 (69) (2,372)
Accounts payable 15,636 (26,083) 20,171
Foreign currency measurement (71) 294 (255)
Contract liabilities (69,302) (61,264) (58,876)
Accrued expenses and other liabilities 764 1,715 30,441
Net cash (used in) provided by operating activities (172,522) (109,141) (92,080)
Cash flows from investing activities:      
Investments in investees (1,200) (1,000) (9,625)
Proceeds from sale of equity securities 0 1,516 2,211
Proceeds from the sale of property, plant and equipment 671 1,223 7,271
Capital expenditures (12,741) (27,858) (46,524)
Net cash used in investing activities (13,270) (26,119) (46,667)
Cash flows from financing activities:      
Issuance of common stock 76,062 92,500 0
Issuance of 2023 Convertible Notes, including to related parties 200,293 55,000 0
Debt issuance costs (7,762) 0 0
Proceeds from the exercise of Common Stock options and warrants (3) 1,173 2,132
Borrowings on lines of credit 294,780 26,917 92,421
Repayments of lines of credit (359,322) (34,681) (33,510)
Redemption of 2033 Senior Notes (28,800) 0 0
Net cash provided by (used in) financing activities 175,248 140,909 61,043
Effect of exchange rate changes on cash and cash equivalents (477) (675) 470
Net increase (decrease) in cash and cash equivalents (11,021) 4,974 (77,234)
Cash and cash equivalents at beginning of period 96,473 91,499 168,733
Cash and cash equivalents at end of period 85,452 96,473 91,499
SUPPLEMENTAL INFORMATION:      
Interest paid 11,873 2,076 1,313
Income taxes paid, net of refunds 2,667 (1,410) 5,416
Operating lease right-of-use assets due to adoption of ASU No. 2016-02 39,380 0 0
Operating lease liabilities due to adoption of ASU No. 2016-02 39,703 0 0
Non-cash financing:      
Shares issued upon the conversion of - Common Stock options and warrants, surrendered in net exercise 20 806 1,546
OPKO Health Europe      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued $ 0 $ 0 $ 304

Source